CLRB Stock Overview
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cellectar Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.16 |
| 52 Week High | US$4.45 |
| 52 Week Low | US$1.43 |
| Beta | 0.99 |
| 1 Month Change | 4.29% |
| 3 Month Change | -3.95% |
| 1 Year Change | 117.93% |
| 3 Year Change | -79.07% |
| 5 Year Change | -84.95% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Feb 12Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
Aug 23
Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19
Aug 05Cellectar announces reverse stock split
Jul 21We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
May 10Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
Jan 20Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Oct 05Cellectar shares fall after mid-stage CLR 131 trial data fails to impress
Jun 04We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely
May 20Cellectar Biosciences EPS beats by $0.03
May 10Cellectar gets notification of formal grant from Australian and Mexican patent authorities
Apr 27Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer
Jan 12Cellectar Bio readies stock offering
Dec 23We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Nov 30
Cellectar Biosciences EPS beats by $0.05
Nov 09Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors
Nov 05Shareholder Returns
| CLRB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | 2.2% | 1.7% |
| 1Y | 117.9% | 5.8% | 26.0% |
Return vs Industry: CLRB exceeded the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: CLRB exceeded the US Market which returned 26.1% over the past year.
Price Volatility
| CLRB volatility | |
|---|---|
| CLRB Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CLRB's share price has been volatile over the past 3 months.
Volatility Over Time: CLRB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 20 | Jim Caruso | www.cellectar.com |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
Cellectar Biosciences, Inc. Fundamentals Summary
| CLRB fundamental statistics | |
|---|---|
| Market cap | US$118.30m |
| Earnings (TTM) | -US$50.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs CLRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLRB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$50.98m |
| Earnings | -US$50.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CLRB perform over the long term?
See historical performance and comparison